The federal state-owned enterprise Shchelkovsky Biocombinat is developing more than 10 new veterinary drugs, the press service of the Ministry of Agriculture and Food of the Moscow Region reports.
The press service reported that over ten new pharmaceuticals are currently in active development. Some are already undergoing state registration, while others are at the stage of pre-clinical and clinical trials. Over the past five years, the facility has developed and launched production of twelve vaccines.
The biocombinat supplies vaccines and other veterinary products to more than 20 countries, with registration procedures underway in six more nations.
The Shchelkovsky Biocombinat is one of Russia’s largest agricultural biological enterprises, manufacturing immunobiological drugs for farm, domestic, and wild animals. Founded in 1924 as a station at Kashintsevskaya breeding farm producing anti-plague serum for pigs, the company now has a product line of over 40 items. Earlier this year, it began production of four new vaccines for the swine industry—targeting circovirus infection, Aujeszky’s disease, porcine reproductive and respiratory syndrome (PRRS), and classical swine fever.
